QIAGEN
Thermo Fisher (TMO) signed a definitive agreement to acquire QIAGEN (QGEN) for 39 Euros per share in cash, currently worth about $42.11. The deal needs various regulatory approvals including HSR, the UK, EU, and China. The deal has committed bridge financing and is not subject to any financing condition.
Deal Process
QIAGEN has a 60% market share of the sample preparation market and competes against the buyer. In particular, they are the market leaders in liquid biopsy, CRISR, and microbiome. Thermo Fisher competes in each. They also compete directly in